In this study, non-directiveness applies to the approach of the counselling team towards family members besides the proband. When a BRCA1/2 gene mutation is found in a family, the possibility of ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Background PARP inhibitors (PARPi) have been licensed for the maintenance therapy of patients with metastatic pancreatic cancer carrying pathogenic germline BRCA1/2 mutations. However, mutations in ...

During the Feb. 11 event, Chris Evert and Martina Navratilova discussed memorable tournaments, double dates and their ...

Most studies assessing BPO are retrospective studies and nonrandomized ( Table 1) and have been evaluated in women at risk for carrying BRCA1/2 mutations. A study by Lu et al [42] reviewed the ...

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

AI chipmaker Nvidia and research partners have created what they call the largest artificial intelligence system yet for ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

cmft.nhs.uk Background While the requirement for thresholds for testing for mutations in BRCA1/2 is being questioned, they are likely to remain for individuals unaffected by a relevant cancer. It is ...

explaining the sensitivity of BRCA1-deficient cancers to therapies that block DNA repair, while mutations that restore HDR cause therapy resistance. Research now reveals a mechanistically distinct ...

BOISE — A bill that would require private Idaho health insurers to cover supplemental breast cancer screenings for high-risk ...